MESO · Mesoblast Limited
$12.28
-2.15% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
27.0
Dividend yield
0.0%
Beta
0.86
Avg volume
0M
Employees
0K
Daily Change %
-2.15%
5 Days Change
-5.50%
10 Days Change
-9.71%
30 Days Change
-17.92%
60 Days Change
-24.58%
Month to Day Change
-12.36%
Year to Day Change
-30.43%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MESO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-27
Latest call per bank · past 12 months
Jefferies
Buy$0.00
-100.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-27 | Piper Sandler | Reiterates | Overweight | $35.00 → $39.00 |
| 2025-11-25 | Jefferies | Upgrade | Hold → Buy | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 35 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 19.3% below the 50-day MA ($15.21).
- bearish: Price vs 200-day MA: Trading 21.0% below the 200-day MA ($15.54).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.10) — short-term momentum is fading.
- bearish: 52-week range: Price is within 10% of the 52-week low ($11.95).
MESO Price Chart
Loading chart for MESO…
Fundamentals
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.